Natera, Inc. Website

Natera, Inc.

NasdaqGS-NTRA

Company Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

  • Name

    Natera, Inc.

  • CEO

    Steven Leonard Chapman

  • Website

    www.natera.com

  • Sector

    Biotechnology

  • Year Founded

    2003

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 6, 2025 - Dec 6, 2025

Natera Inc Surges 22.2% Amid Strategic Developments and Insider Confidence

  • Natera's participation in major medical conferences enhances its visibility in the oncology sector.
  • Insider trading activity reflects strong confidence from company leadership regarding future performance.
  • Despite mixed financial results, management raised annual revenue guidance for FY2025.

Over the past month, Natera Inc (NTRA) experienced a significant stock price increase of 22.2%, markedly outperforming the S&P 500's return of 1.2%. This growth can be attributed to several key developments that bolstered investor sentiment towards the company. A highlight was Natera’s announcement of its participation in important medical conferences, particularly the San Antonio Breast Cancer Symposium, where it plans to present twelve datasets involving over 50,000 patients related to its Signatera™ product. This proactive approach is expected to enhance credibility within the oncology sector and solidify Natera’s position as a leader in precision medicine.

Insider trading activity also contributed positively during this period. Director Baynes Roy D.D exercised options for shares at favorable prices, indicating strong insider confidence in the company's future value despite some bearish signals from social media discussions about portfolio adjustments by prominent investors like Stanley Druckenmiller who holds a substantial stake in NTRA. Overall market sentiment remained positive due to robust revenue growth reported earlier.

However, moments of volatility arose following mixed financial results released on November 7th; while revenues surpassed expectations at $592 million—a year-over-year increase—Natera recorded larger-than-expected losses per share that raised concerns among some investors regarding profitability sustainability amidst high operational costs. In response to these challenges, management significantly raised their annual revenue guidance for FY2025.

Throughout this month-long period marked by strategic presentations and insider activities alongside fluctuating earnings reports, analysts maintained a consensus recommendation leaning towards "Moderate Buy." They recognized Natera's potential for growth amid ongoing innovations within molecular diagnostics services. Compared with broader market trends where the Health Care sector (XLV) showed an overall performance lagging behind at just over 5%, it is evident that Natera Inc outperformed both its sector peers and general market indices effectively by showcasing resilience through strategic initiatives and consistent revenue generation efforts.

Natera Inc outperformed the Health Care (XLV) sector by 17.0%.

NasdaqGS:NTRA